Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2^nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. 

A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. 

About Corvus Pharmaceuticals 
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com. 

INVESTOR CONTACT: 
Leiv Lea 
Chief Financial Officer 
Corvus Pharmaceuticals, Inc. 
+1-650-900-4522 
[email protected]  

MEDIA CONTACT: 
Sheryl Seapy 
Real Chemistry 
+1-949-903-4750